BACKGROUND: Racial disparities in cancer outcomes have been described. To the authors' knowledge, it remains unclear whether patients of Hispanic ethnicity have better or worse survival outcomes. In the current study, the authors evaluated whether Hispanic participants in SWOG clinical trials had different survival outcomes compared with non-Hispanics. METHODS: Adult patients registered in SWOG phase 2/3 clinical trials between 1986 and 2012 were analyzed. Studies of similar histology and stage of disease were combined. Within each analysis, Kaplan-Meier survival curves were generated to examine differences in outcome by ethnicity. Multivariate Cox regression was used to estimate the association between ethnicity and survival outcomes, controlling for major diseasespecific prognostic factors and demographic variables plus area-level income and education to account for socioeconomic status. RESULTS: A total of 29,338 patients registered to 38 trials were included; 5% of these patients were Hispanic. Hispanic patients were more likely to be younger and from areas of lower income and education (all P<.05). No differences in survival were observed across tumor types except in the patients with advanced stage prostate cancer, in whom the authors observed an association between Hispanic ethnicity and worse overall survival (hazard ratio [HR], 1.40; P 5 .006), progression-free survival (HR, 1.36; P 5 .007), and cancer-specific survival (HR, 1.42; P 5 .013). After adjusting for multiple comparisons, no differences in outcomes were noted. CONCLUSIONS: Hispanic patients participating in SWOG trials who received uniform treatment and follow-up were found to have similar survival outcomes compared with non-Hispanic patients, with the single exception of those patients with advanced stage prostate cancer. The results of the current study demonstrate that Hispanic patients receiving uniform treatment and follow-up have similar outcomes compared with non-Hispanics. Cancer 2018;124:1760-9.
INTRODUCTION
Over the last few decades, a sustained decline in cancer mortality has been evident. 1 Declines in cancer death rates have been noted for men and women across all ethnic and racial groups. However, the mortality decline has been consistently greater among white individuals compared with African American or Hispanic individuals, 1 suggesting that therapeutic advances are not benefiting all patients equally. 2, 3 Although differences in tumor biology are likely contributing, differences found within tumor subsets suggest that sociodemographic factors such as access to quality care or timely treatment could play a role.
Hispanics represent the largest ethnic minority group in the United States, accounting for 17.4% of the total population. 4 Projections indicate that the size of this population will double by 2050, 5 suggesting the importance of evaluating outcomes for this ethnic group. Hispanics have different behavioral and environmental exposures and a high prevalence of important cancer risk factors such as obesity and diabetes. Among Hispanic individuals, cancer is the leading cause of death, 6 and Hispanics are more likely to be diagnosed with advanced stages of disease compared with their non-Hispanic counterparts. Recent reports have suggested that the cancer death rates among Hispanics are 30% lower compared with non-Hispanic whites; however, these observed discrepancies may be exaggerated due to incomplete death ascertainment and challenges associated with follow-up. 6 To the best of our knowledge, comprehensive analyses using prospective data across a broad range of cancers comparing outcomes among Hispanic and non-Hispanic individuals have not been conducted to date.
In the current study, we evaluated outcomes of patients with cancer who were treated in clinical trials according to Hispanic ethnicity. Studying clinical trial participants allows for the analysis of a homogenous patient population with known baseline prognostic factors, controls for treatment, and follows patients similarly at regular intervals with a reliable assessment of outcomes. To the best of our knowledge, this is the first study to evaluate outcomes according to Hispanic ethnicity in a large cohort of clinical trial participants controlling for demographic and clinically relevant variables.
MATERIALS AND METHODS
The data included in this analysis originated from SWOG, a National Cancer Institute-sponsored clinical trials consortium. Beginning in the late 1980s, SWOG routinely collected self-reported data regarding ethnicity (Hispanic vs non-Hispanic). We systematically examined the SWOG trials from 1986 through 2012. We considered only published phase 3 or large phase 2 trials enrolling adult patients with available ethnicity data.
Given that the Hispanic population in the United States has a younger age distribution, and cancer occurs primarily among older individuals, the percentage of patients with Hispanic ethnicity in trials often is small. To increase power, we combined trials according to disease site, histology, and stage. The primary outcome was overall survival (OS), measured as days from registration to last contact (censored) or death from any cause. We also examined progression-free survival (PFS) and cancerspecific survival (CSS) as secondary outcomes. PFS was defined as days from registration to last contact (censored), death from any cause, or evidence of disease recurrence or progressive disease. CSS was measured as days from registration to cancer-specific death, death from another cause (censored), or last contact (censored). Approximately 29% of patient deaths were accompanied by detailed cause-of-death information. For the remaining 71%, any death preceded by documented disease recurrence or progression was considered a cancer-specific death. All analyses were limited to the first 5 years after registration to focus on cancer-related and treatmentrelated survival. Patients with a date of last contact or death date that was >5 years after registration were censored at 5 years.
Statistical Analysis
Kaplan-Meier survival curves were generated for each analysis separately for Hispanic and non-Hispanic patients. Multivariate Cox regression was used to estimate the effect of Hispanic ethnicity on OS, PFS, and CSS while controlling for disease-specific prognostic factors and sociodemographic variables. Each analysis accounted for age, race, and sex. To account for differences in socioeconomic status (SES) and educational level, SES was estimated using patient zip code. Zip code was linked to median household income and the percentage of residents who completed high school via 2000 US census data. If the median household income in a patient's zip code was higher than the overall 2000 US median household income, the patient was designated as being of high income. A similar method used the percentage of residents who completed high school in a given zip code to define the area as having a high or low educational level. In addition, each analysis accounted for important diseasespecific clinical adjustment variables. Only clinical adjustment variables with a known effect on survival that were measured in all studies within an analysis were included. Supporting Information Table 1 provides a complete list of the variables included in the multivariable model for each tumor subtype category. Each analysis was stratified by study. Results were expressed as hazard ratios (HRs) and 95% confidence intervals (95% CI). Follow-up was truncated at 5 years to emphasize survival related to cancer diagnosis and treatment. In addition to disease-specific analyses, we also conducted an omnibus test of the global trend across the different analyses, based on a 1-sample Student t test of the analysis-specific (signed) chi-square statistics representing the test of the statistical significance of the association of ethnicity and outcome in the multivariable regression models.
Because males represented a very small percentage of the patients with breast cancer, they were removed from the breast cancer analyses. Among patients with nonHodgkin lymphoma, the International Prognostic Index was included as a covariate; because the calculation of this index considers age, non-Hodgkin lymphoma analyses did not include age. Finally, because there were relatively few patients in the advanced breast cancer group who were estrogen receptor (ER) and progesterone receptor (PR) negative, only those patients who were ER and/or PR positive were included. We conducted multiple sensitivity analyses: 1) we compared survival outcomes between Hispanic and non-Hispanic white individuals (rather than all non-Hispanics); 2) we excluded income and educational level; 3) we limited follow-up to the first 10 years after randomization (rather than the first 5 years only); 4) we examined alternative approaches to identifying cancer-specific deaths; and 5) we examined the potential for different trends in the association between ethnicity and outcomes between patients enrolled before versus after the year 2000. All analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). All tests were 2-sided and used an exploratory significance level of a 5 .05. Observed P values also were compared with a multiple comparisons Bonferroni-adjusted P value level. Assuming independent testing for a given endpoint (eg, OS), this level was calculated at P 5 .0036 (P 5 .05 divided by 14 analyses per endpoint type). Power calculations encompassing the range of sample sizes used in this analysis are shown in Supporting Information Table 2 .
RESULTS
In total, we obtained patient data from 38 unique trials totaling 37,548 enrollments. A total of 8210 patients were missing data regarding Hispanic ethnicity, zip code, or one of the important clinical adjustment variables, leaving 29,338 patients available for inclusion in 14 separate analyses (Table 1) .
Patient Characteristics
Patient characteristics and clinical prognostic factors according to cancer type are shown in Table 2 . Approximately 5% of the participants were Hispanic. Patient characteristics and clinical prognostic factors according to Hispanic ethnicity are shown in Table 3 . Hispanic patients participating in SWOG clinical trials were younger and less likely to report being African American. In addition, they lived in areas of lower income and educational levels (all P<.05). There were very few statistically significant differences noted between Hispanic and nonHispanic patients with respect to clinical prognostic factors.
Outcomes by Ethnicity Status Figure 1 shows Kaplan-Meier OS curves comparing Hispanic and non-Hispanic patients. There were no clear differences observed according to Hispanic ethnicity with regard to OS; the only exception was among patients with advanced prostate cancer, among whom Hispanic individuals had worse survival. It is interesting to note that no survival differences were observed among patients with hormone-refractory advanced prostate cancer. .02]). There were no other statistically significant differences noted with regard to survival outcomes. Importantly, none of these results achieved statistical significance under a multiple testing P value level of .0036. Results from the multivariable Cox models are illustrated in Figure 2 . There was no evidence of a general trend toward better or worse outcomes for Hispanic patients across the panel of different analyses according to the global tests.
Sensitivity Analyses
When using non-Hispanic white individuals as the reference category, the results remained grossly unchanged (see Supporting Information Fig. 1 ). The exclusion of SES variables changed some of the results, highlighting the importance of social factors in cancer outcomes. Similar to the full model, Hispanic patients with advanced stage prostate cancer had worse outcomes. Hispanic patients with early-stage ER-positive and/or PR-positive breast cancer were found to have worse PFS compared with their non-Hispanic counterparts. Hispanics with early-stage ER-negative and PR-negative breast cancer had better CSS than non-Hispanic patients. Otherwise, there were no statistically significant differences observed between Hispanic and non-Hispanic patients (data not shown). In no disease group was there evidence that the association between Hispanic ethnicity and outcome differed between categories of education or income using interaction tests. Sensitivity analyses evaluating a longer follow-up of 10 years are shown in Supporting Information Figure 2 , indicating generally similar results. We examined different approaches to identifying cancer-specific deaths, and found no global pattern of better or worse cancer-specific deaths for Hispanic patients under any of 3 alternative scenarios (see Supporting Information Fig. 3 ). Finally, we found no instances of statistically significant associations between Hispanic ethnicity and outcomes in the opposite directions between patients enrolled before and after the year 2000, and there was no statistically significant evidence that global patterns in the 3 outcomes (OS, PFS, and CSS) differed between patients registered before versus after the year 2000 (data not shown).
DISCUSSION
In this large cohort of patients participating in therapeutic SWOG clinical trials, we found little evidence that OS, Original Article 6 The mortality rate for males (per 100,000 population and age adjusted to the 2000 US standard population) is estimated to be 148 for Hispanics and 211 for non-Hispanic whites; among females, mortality rates are 99.4 and 149.2, respectively. This differential mortality favoring Hispanics has been reported across tumor types and across other chronic diseases and is known as the "Hispanic paradox." This term refers to the epidemiological finding that Hispanic individuals in the United States tend to have substantially better health outcomes compared with the average population despite what their aggregate socioeconomic indicators would predict. [7] [8] [9] [10] In the current study, using a homogenous population of clinical trial participants, after controlling for important clinical factors, we demonstrated similar survival outcomes among Hispanic patients compared with non-Hispanic patients. It is important to note that the patients included in the current study cohort were treated with similar protocols and were followed prospectively in a uniform fashion. The findings of the current study suggest that current therapies provide similar benefits regardless of Hispanic ethnicity. This finding is important, because cancer among Hispanics accounted for 126,000 new cancer cases in 2015. 6 Moreover, an increasing number of cancer cases among Hispanics is expected in the future because Hispanic individuals in the United States are younger on average and cancers are more common in older patients. 5, 11 The only group of patients among whom we observed a detriment in outcomes was the advanced prostate cancer group, although this difference was not statistically significant under multiple testing. Also of interest is the absence of any pattern of statistically significant associations for patients with advanced, hormone-refractory prostate cancer. It is interesting to note that this patient group only included registrations beginning the year 1999, whereas patients with advanced prostate cancer were enrolled from 1989 through 2008. Although we found no general pattern of temporal trends in the association between ethnicity and outcomes, temporal trends could be influential in this disease setting. Differential outcomes according to race/ethnicity have been reported in patients with prostate cancer; it has been described that African American patients have a mortality rate double that of white men. [12] [13] [14] In an analysis similar to that 51.5%
Abbreviations: 1, positive; -, negative; AML, acute myelogenous leukemia; ER, estrogen receptor; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PR, progesterone receptor; PSA, prostate-specific antigen.
a Study S0012 did not collect baseline information regarding the number of positive lymph nodes. To include patients from S0012 in the analyses, a dummy covariate was created to denote missing information regarding lymph node involvement. Similarly, because approximately 11% of the patients in the advanced breast cancer group had missing HER2 status, a dummy covariate was created to denote HER2 status missing information. presented herein, Albain et al reported that, after adjusting for important covariates, African American patients with prostate cancer, despite being treated similarly, had a 19% increased risk of dying compared with white patients. 3 To the best of our knowledge, relatively few studies to date have reported the mortality rates among Hispanic patients with prostate cancer. A recent study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database reported similar all-cause and prostate cancer-specific mortality rates for Hispanics when compared with non-Hispanic whites. 15 In the models before adjusting for multiple comparisons, we observed that among patients with advanced prostate cancer, Hispanics had an increased risk of dying. It is possible that comorbidities, obesity, or differences in the volume of the disease could have had an effect on outcome. 6, 12, [16] [17] [18] Although the implications of worse outcomes among Hispanic patients with prostate cancer could be relevant considering that prostate cancer is the most frequent cancer diagnosed in Hispanic males (22% of cases), we must emphasize that after adjusting for multiple comparisons, this difference was no longer of statistical significance.
In our sensitivity analysis excluding SES-related variables, Hispanic patients with ER-positive and/or PRpositive early-stage breast cancer had significantly worse PFS compared with non-Hispanic patients. Although the benefit of adjuvant endocrine therapy among these patients is unquestionable, the therapy is prolonged and costly and this could have a differential effect among Hispanics, who are known to have overall lower income and educational levels compared with whites. Early discontinuation of endocrine therapy is a frequent problem. 19, 20 In what to our knowledge is the largest study to date evaluating adherence in this group of patients, a 32% rate of early discontinuation was observed. 21 Early discontinuation and nonadherence have been associated with worse outcomes, and patients of ethnic minorities and disadvantaged income and educational levels are particularly vulnerable. 22, 23 Unfortunately, in the current analysis, we were not able to take into account adherence to adjuvant endocrine therapies.
Despite the strengths of our unique analysis, we acknowledge that the cohort of patients may not represent the characteristics of the overall Hispanic population. Just 5% of patients overall were Hispanic, which actually is greater than the percentage of Hispanics in the population for the age distribution represented by clinical trial patients. 24 Nonetheless, this low rate presents potential issues with respect to both selection bias and statistical power. It is well known that clinical trial participants tend to be younger and healthier, have fewer comorbidities, and belong to higher SES and educational levels compared with nonparticipants. [25] [26] [27] Different studies have characterized clinical trial participants, with some suggesting that ethnic minorities are underrepresented. 3, 28 In addition, it is clear that clinical factors such as performance status, number of comorbid conditions, and cancer stage also determine clinical trial participation. 29 We cannot exclude the possibility that Hispanics participating in SWOG clinical trials have biological and sociodemographic characteristics that differ from those of the general Hispanic population. However, although these factors likely influence overall estimates of survival outcomes, they are less likely to influence relative differences by ethnicity. Finally, the analysis of CSS was limited by the absence of specific cause-of-death information for many patients. Despite these limitations, we believe the current study is the first to demonstrate that, when treated homogenously, Hispanic patients have similar outcomes compared with non-Hispanic patients. Efforts should continue to promote and engage ethnic minorities to participate in clinical trials. Only by including large and representative samples of patients in clinical trials will we be able to ensure generalizability of the obtained results to the entire population.
To the best of our knowledge, the current study is the first to report, in a large cohort of clinical trial participants, outcomes according to Hispanic ethnicity. After adjusting for multiple comparisons, no notable differences in survival outcomes by ethnicity were evident, Figure 2 . Multivariable analysis of overall survival, progression-free survival, and cancer-specific survival according to Hispanic ethnicity by tumor site analysis. 1 indicates positive; -, negative; 95% CI, 95% confidence interval; AML, acute myelogenous leukemia; ER, estrogen receptor; GIST, gastrointestinal stromal tumor; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PR, progesterone receptor.
